title: New antimicrobial molecules and new antibiotic strategies.
abstract: Drug options for treatment of infections are increasingly limited. The pharmaceutical industry has found it difficult to discover new antimicrobial agents, and only two novel classes of antibiotics, the oxazolidinones and the cyclic lipopeptides, have entered the market since the late 1960s. Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin. Agents currently in clinical development include other novel quinolones and ketolides, broad-spectrum cephalosporin derivatives, faropenem, several glycopeptides, and iclaprim. Other molecules are considered to be promising candidates for the future. In addition to the foregoing agents, alternative treatment approaches have also been introduced into clinical practice, which include the administration of the appropriate antimicrobials in a timely manner and the consideration of the pharmacokinetic-pharmacodynamic properties of the agent(s).
authors.affiliation: Servicio de Neumología, Hospital Universitario de Gran Canaria Dr. Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain. frodcasw@gobiernodecanarias.org
authors.forename: Felipe
authors.initials: F
authors.lastname: Rodríguez de Castro
authors.forename: Olga Rajas
authors.initials: OR
authors.lastname: Naranjo
authors.forename: Javier Aspa
authors.initials: JA
authors.lastname: Marco
authors.forename: Jordi Solé
authors.initials: JS
authors.lastname: Violán
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy; D015195:Drug Design; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D000077727:Ertapenem; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D048628:Ketolides / Q000627:therapeutic use; D000069349:Linezolid; D055666:Lipopeptides / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D047090:beta-Lactams / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D048628:Ketolides; D055666:Lipopeptides; D023303:Oxazolidinones; D047090:beta-Lactams; C073460:cefditoren; D000077727:Ertapenem; D000069349:Linezolid; C106791:telithromycin